THE-NAGA-GROUP-AG
20.5.2020 15:00:06 CEST | Business Wire | Press release
The NAGA Group continues its high growth rate and announces new projects.
With NAGA Pay, NAGA will be launching its own challenger bank app, which for the first time combines mobile banking, trading, social trading and cryptocurrency trading.
"NAGA Pay is an ambitious project with great growth potential. In recent years we have gained a lot of experience in building a real-time trading platform with a clear monetization model across a wide range of asset classes. Our trading app and our cryptocurrency platform have processed millions of transactions. In parallel, our NAGA Card programme, which offers our customers a prepaid Mastercard and a European IBAN account, has shown very promising growth rates. We have also followed the projects in the multi-billion NEO-Banking / Challenger-Bank segment very closely and have created all the prerequisites to become part of this segment. Hence, we have decided to combine all our expertise in NAGA Pay and are currently developing a super app for mobile banking and investing. The entry into the payment vertical underlines the FinTech character of our company and will offer us new customer acquisition and growth opportunities without losing our focus on the core business", says Benjamin Bilski, founder and CEO of The NAGA Group AG.
NAGA Pay will be launched around the beginning of Q4 2020 as a separate native iOS- and Android app. The app combines the offer of a prepaid credit card, a European IBAN bank account with limits of up to € 200,000 per year and complete banking functions such as SEPA transfers. In addition to real-time money transfers and money management, NAGA customers can trade over 400 stocks from 9 global stock exchanges free of charge, as well as copy other top traders with one click. The offer is completed with the integration of the NAGA Wallet and NAGAX, so that customers can buy and sell physical cryptocurrencies with NAGA Pay and make blockchain-based deposits and withdrawals.
For more information and to register to the NAGA Pay waiting list https://www.naga.com/pay has been launched today.
Furthermore, NAGA is delighted to announce the launch of NAGA Pro. NAGA Pro is aimed specifically at users who already run their own financial trading community, are pursuing a career as a professional trader or want to build a business model in the trading space. NAGA-Pro offers its users a monthly base remuneration and a lucrative performance package if certain criteria are met, thereby creating a unique "digital influencer" model.
"NAGA Pro is a real growth catalyst for us. Due to the high level of investment in our own trading platform and our cooperation with 600,000 users and 1,500 partners, we understand the needs of users as well as professional traders, trainers and operators in the wider trading and investing world. We see this as a slight adjustment in our business model and positioning. Instead of plunging into the very expensive and "innovation-free" marketing battle for retail customers, we want to use our technology offer in a focused manner by helping entrepreneurs and businesses accelerate their growth and ultimately to grow together with us. In a nutshell, NAGA Pro is a tool for traders, professionals, and for all those with business models focused around trading who bring their community and followers with them or build up a community within NAGA. Thereby we will differentiate ourselves from the competition and expand our marketing and sales focus accordingly", commented Bilski.
The NAGA Pro model is already successfully practiced at NAGA. With pilot projects in Asia and Poland that started at the beginning of the year, over 30% of the total turnover can be attributed to the NAGA Pro pilots.
"Our unique selling point as the most innovative and user-friendly platform on the market is underpinned by NAGA Pro. The proof of concept has been delivered. We therefore see ourselves in the highly encouraging situation of being able to offer a "Platform-as-a-Service" or, as our NAGA Pro users say so nicely - "The Uber model for investing" - which is aimed at the operator and not only at the end user", adds Benjamin Bilski.
Further information on NAGA Pro can be found on the dedicated website naga.com/pro .
Finally, the company reports the preliminary results of April and the start of the project in China.
In April, NAGA achieved a strong revenue result of around € 2.2 million and a preliminary net profit of around € 0.6 million and therefore continued the strong growth and earnings momentum built in Q1 (Q1: revenues € 7.0 million, net profit €2.1m). In addition, a new record number of registrations was recorded in April, which can be seen as the foundation for further growth. NAGA is also delighted to report that the first transactions of the NAGA China project were processed during May, with management expecting further growth in the course of Q3 and especially Q4.
"We are fully dedicated to growth, we want to keep the momentum high and continue to show how much potential there is in NAGA's unique platform and our business model. Another focus of the next few months will be the optimization of acquisition costs, sustainable growth and, above all, the addition of new personnel, as we have just posted around 30 new vacancies," concludes Benjamin Bilski.
###
About NAGA
NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical Mastercard and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.
| Language: | English |
| Company: | The NAGA Group AG |
| Hohe Bleichen 12 | |
| 20354 Hamburg | |
| Germany | |
| E-mail: | info@naga.com |
| Internet: | www.naga.com |
| ISIN: | DE000A161NR7 |
| WKN: | A161NR |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005489/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom